1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Deals

Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn't

 
• By Malcolm Spicer

Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.

TheraTears OTC dry eye drop line is the centerpiece of Prestige Consumer Healthcare's deal with Akorn for five consumer brands. • Source: Akorn

Prestige Consumer Healthcare Inc.’s portfolio expansion, notably with the TheraTears OTC dry eye drop brand, is Akorn Inc.’s exit from consumer health, even though its lineup still includes an OTC drug and a dietary supplement.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Astaxanthin Specialist AstaReal Diversifies With Garlic Supplement For Heart Health

 
• By Tom Gallen

Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.

Italy’s PharmaNutra Grows Presence In Americas And MENA

 
• By Tom Gallen

Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.

Azelis Grows Nutraceuticals Offering In Iberia With Solchem

 
• By Tom Gallen

Azelis adds dietary supplement ingredients and a large customer base across Spain to its portfolio with the acquisition of Solchem Nature.

Australia’s Wellnex Life Poised To Enter UK’s CHC Market

 
• By Tom Gallen

Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.

More from Business

Abbott Lifts Curtain For Consumer Health Sector Results On ‘Dynamic Environment’ From Tariffs

 
• By Malcolm Spicer

“As we progress through 2025, it is clear that we are operating in an increasingly dynamic environment,” says Abbott CEO Robert Ford. Trump’s tariff decisions, the CRN advises dietary supplement and other consumer health product firms, are likely to change.

Italy’s PharmaNutra Grows Presence In Americas And MENA

 
• By Tom Gallen

Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.

French Agency Proposes Effective EU Ban On CBD In Foods And Cosmetics

 
• By David Ridley

France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.